See more : Winton Land Limited (WTN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Citius Pharmaceuticals, Inc. (CTXR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Citius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vicinity Motor Corp. (VMC.V) Income Statement Analysis – Financial Results
- King Global Ventures Inc. (KGLDF) Income Statement Analysis – Financial Results
- Consilium Acquisition Corp I, Ltd. (CSLMU) Income Statement Analysis – Financial Results
- Priority Income Fund, Inc. (PRIF-PF) Income Statement Analysis – Financial Results
- Pilani Investment and Industries Corporation Limited (PILANIINVS.NS) Income Statement Analysis – Financial Results
Citius Pharmaceuticals, Inc. (CTXR)
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -194.32K | -179.68K | -164.87K | -152.36K | -893.00 | -1.75K | -2.63K | -1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.82M | 17.66M | 12.24M | 8.81M | 8.60M | 6.56M | 2.94M | 2.93M | 1.80M | 437.97K | 492.14K | 705.81 | 0.00 |
| General & Administrative | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 310.30 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.31K | 0.00 |
| SG&A | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 19.62K | 25.64K |
| Other Expenses | 0.00 | 1.45M | 59.92K | 110.21K | 715.98K | 1.27M | 732.15K | 732.15K | 486.27K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Cost & Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Interest Income | 1.18M | 251.40K | 261.83K | 68.07K | 52.66K | 0.00 | 806.00 | 806.00 | 3.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 251.40K | 10.84K | 15.67K | 16.44K | 15.84K | 850.79K | 8.99K | 7.50K | 0.00 | 3.25K | 2.39K | 0.00 |
| Depreciation & Amortization | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 3.07K | 1.15M | 1.18M | 1.02K | 704.00 |
| EBITDA | -36.73M | -32.88M | -22.88M | -17.38M | -15.54M | -13.79M | -9.98M | -7.45M | -3.23M | 0.00 | 0.00 | -19.62K | -24.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.73M | -33.32M | -23.53M | -17.71M | -15.60M | -13.79M | -9.99M | -7.45M | -3.23M | -1.15M | -28.12K | -19.62K | -25.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.77M | 251.40K | 477.46K | 162.60K | 36.22K | 1.25M | -398.64K | -846.41K | 327.66K | 171.82K | 0.00 | -2.39K | -704.00 |
| Income Before Tax | -31.97M | -33.06M | -23.05M | -17.55M | -15.56M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 576.00K | 576.00K | 70.76K | 125.88K | 16.44K | 1.28M | 850.79K | 8.99K | 4.43K | -119.15K | -1.18M | -1.02K | 0.00 |
| Net Income | -32.54M | -33.64M | -23.13M | -17.67M | -15.58M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.23 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| Weighted Avg Shares Out | 146.13M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
| Weighted Avg Shares Out (Dil) | 151.29M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval marks the first novel targeted systemic therapy approved by...
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction...
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to...
Analysts Hunt for Undervalued Biotech Stocks
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to...
Bloodstream Infections - From Threats to Solutions
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc....
Biopharma Stocks Transformative Innovation for the Future of Health
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company...
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Multiple catalysts for potentially transformative assets in second half of 2024 Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if approved First-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR...
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J. , May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of...
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
Citius Pharmaceuticals (NASDAQ: CTXR ) stock is on the rise Tuesday after the company announced new results from its Phase 3 clinical trial of Mino-Lok. Mino-Lok is Citius Pharmaceuticals' antibiotic lock solution for patients with central line-associated infections or catheter-related...
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients retaining their catheters (p=0.0025) CRANFORD, N.J. , May 21, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the...
Source: https://incomestatements.info
Category: Stock Reports